$10.210
+0.395 (+3.87%)收盘时
PBYI 资讯
PBYI 事件
Nasdaq Composite Rises 1.7% as Fed Policy Turns Hawkish
The overall interpretation of yesterday's Fed policy decision was overwhelmingly hawkish, and yet the broadly constructive reaction in risk assets and the decline in Treasury yields served up a reminder that - above all else - markets hate uncertainty. Tech-heavy Nasdaq Composite led the other indices with a 1.7% advance while S&P 500 - led by Technology, Basic Materials, and Consumer Cyclical sectors - rallied 1.1%, nearly erasing the decline of the past three sessions.The yield on the 10-year fell back below 5%, slipping 6 basis points to 4.95%, and the lower funding costs, in turn, supported the AI capex buildout areas within Technology - eight out of the ten best-performing stocks in the S&P 500, including Intel, AMD, and Sandiskwere in the tech space. A sharp decline in energy prices amid reports that Saudi Arabia is offering additional crude cargoes through Oman also helped restore a calmer narrative for the market - WTI Crude Oil is now below $97 per barrel, $10 lower from its multi-month peak just three days ago.In the opening hour of the evening session, index futures are marginally lower, with e-minis and Nasdaq 100 down by a decimal.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER -Skillsoftup 5.2% after insider buyCooper Companiesup 2.8% after WSJ report that Jana Partners is calling for CEO change and core business evaluationPuma Biotechnologyup 1.9% after start of Phase 2 study of alisertib in small cell lung cancerLOWER -Xenon Pharmaceuticalsdown 26.7% after pausing depression study enrollmentSteel Dynamicsdown 3.8% after below-consensus pre-announcementNucordown 3.3% after below-consensus pre-announcement
Puma Biotechnology Initiates Phase II Trial for Small Cell Lung Cancer
Puma Biotechnology "announced the initiation of its ALISertib in CAncer Phase II trial of alisertib in combination with paclitaxel for the treatment of patients with advanced small cell lung cancer. The ALISCA(R)-Lung2 trial is a sequential dose escalation study that will enroll approximately 50 patients with small cell lung cancer who have progressed on or after treatment with platinum-based chemotherapy and immunotherapy. The primary endpoint of the trial is the safety and tolerability of alisertib when administered with paclitaxel. Secondary endpoints include objective response rate, duration of response, disease control rate, progression-free survival and overall survival. Puma will also evaluate clinical biomarkers to help identify which patients have the greatest benefit to guide the future development of alisertib."
Sees Q3 Royalty Revenue of $2M-$3M
Sees Q3 royalty revenue $2M-$3M, net product revenue $54M-$56M
Sees FY26 Net Revenue at $202M-$206M
Sees FY26 net produce revenue $202M-$206M, sees FY26 royalty revenue $20M-$23M
Puma Reports Q2 Revenue of $56.5M, Up 8% Year-over-Year
Reports Q2 revenue $56.5M vs $52.4M last year. "We are pleased with our commercial execution in the second quarter and the continued increase in year-over-year demand for NERLYNX. We are also pleased with our continued progress across our clinical development programs during the second quarter," said Alan H. Auerbach, Chairman, Chief Executive Officer and President of Puma. "We remain focused on both continuing our commercial execution in the second half of the year as well as with continuing to advance alisertib in the respective ALISCA clinical trials in HER2-negative, hormone receptor-positive metastatic breast cancer and small cell lung cancer."
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。